Track topics on Twitter Track topics that are important to you
Shanghai Fosun Pharma's $1.3 billion acquisition of a majority stake in India's Gland Pharma is in trouble. It may be rejected by India, not because of the deal itself, but because China and India are in a military stand-off over a small piece of land in the Himalayas, according to a Bloomberg article. The two countries fought a border war over the territory in 1962, and now the border is back in dispute. The Fosun-Gland deal could end up being collateral damage in a larger conflict between the world's two most populous nations. More details....
Stock Symbols: (SHA: 600196; HK: 2196)
Share this with colleagues:
Original Article: India May Reject Fosun's $1.3 Billion Acquisition of Gland PharmaNEXT ARTICLE
Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...